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Research Article
Effects of JWH015 in cytokine secretion
in primary human keratinocytes and
fibroblasts and its suitability for
topical/transdermal delivery
Alicia Bort1,2,*, Perla A Alvarado-Vazquez2,*,
Carolina Moracho-Vilrriales1, Kristopher G Virga2,
Giuseppe Gumina2, Alfonso Romero-Sandoval2 and Scott Asbill2
Abstract
Background: JWH015 is a cannabinoid (CB) receptor type 2 agonist that produces immunomodulatory effects. Since skin
cells play a key role in inflammatory conditions and tissue repair, we investigated the ability of JWH015 to promote an anti-
inflammatory and pro-wound healing phenotype in human primary skin cells.
Methods: Human primary keratinocytes and fibroblasts were stimulated with lipopolysaccharide. The mRNA expression of
cannabinoid receptors was determined using RT-PCR. The effects of JWH015 (0.05, 0.1, 0.5, and 1 mM) in pro- and anti-
inflammatory factors were tested in lipopolysaccharide-stimulated cells. A scratch assay, using a co-culture of keratinocytes
and fibroblasts, was used to test the effects of JWH015 in wound healing. In addition, the topical and transdermal penetration
of JWH015 was studied in Franz diffusion cells using porcine skin and LC-MS.
Results: The expression of CB1 and CB2 receptors (mRNA) and the production of pro- and anti-inflammatory factors
enhanced in keratinocytes and fibroblasts following lipopolysaccharide stimulation. JWH015 reduced the concentration of
major pro-inflammatory factors (IL-6 and MCP-1) and increased the concentration of a major anti-inflammatory factor (TGF-
b) in lipopolysaccharide-stimulated cells. JWH015 induced a faster scratch gap closure. These JWH015’seffects were mainly
modulated through both CB1 and CB2 receptors. Topically administered JWH015 was mostly retained in the skin and
displayed a sustained and low level of transdermal permeation.
Conclusions: Our findings suggest that targeting keratinocytes and fibroblasts with cannabinoid drugs could represent a
therapeutic strategy to resolve peripheral inflammation and promote tissue repair.
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Introduction
Tissue damage (i.e. surgeries, autoimmune conditions,
chemotherapy, diabetes, herpes infections, etc.) triggers
an inflammatory process that could result in chronic
wounds, ulcers, irritation, pruritus, neuropathies or even
sensitization of peripheral nociceptors, allodynia, and
hyperalgesia.1 Persistent peripheral inflammatory pro-
cesses could subsequently induce changes in the central
nervous system if they do not resolve in a timely fashion,
as observed in major surgeries, rheumatoid arthritis,
chemotherapy-induced neuropathy, diabetic peripheral
neuropathy, and post-herpetic neuralgia. Therefore, a per-
sistent peripheral inflammatory condition may result not
only in chronic peripheral tissue damage but also in
chronic pain.2 Current available therapies for chronic
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pain with prominent peripheral pathologic mechanisms
act mostly in the central nervous system (antidepressants
and anticonvulsants, cannabinoids, etc.), which not only
induce many undesirable side effects but also provide par-
tial relief only in a sub-population of patients.3,4
Pre-clinical models of inflammatory neuropathy have
shown that targeting the peripheral source of inflamma-
tion (using clonidine) reduces pain-related behaviors in
rats.5–7 In clinical studies, the peripheral administration
of clonidine reduces pain in patients with diabetic neur-
opathy.8,9 Likewise, an 8% capsaicin patch is part of the
current available arsenal to treat post-herpetic neural-
gia.10,11 These data provide a compelling argument in
favor of peripherally directed therapies for the treatment
of chronic pain with a predominant peripheral origin.
The major advantage of these therapeutic strategies
is the avoidance of central penetration to retain a desir-
able effect restricted to the periphery (i.e. topical drug
administration and drugs that act on peripherally
restricted targets), which will reduce central undesirable
side effects (sedation, respiratory depression, paranoia,
tolerance, etc.).
Due to the efficacy of cannabis in some types of chronic
pain conditions,12 synthetic cannabinoid molecules have
been extensively studied in pre-clinical models with signifi-
cant findings.13,14 Even though cannabinoids could bind
to different receptors (i.e. TRP channels, PPARs, GPR55,
etc.), the effects of cannabis or other cannabinoids are
mostly due to their actions on cannabinoid (CB) receptors
type 1 (CB1), located mostly in the central nervous
system, and CB receptors type 2 (CB2), located mostly
in the periphery.15,16 The major limitation of non-selective
cannabinoids is their psychotropic side effects that depend
upon central CB1 receptor activation.17 Therefore, target-
ing peripheral CB1 receptors for the treatment of pain
seems a safer pharmacological approach. Since CB2
receptors are predominantly expressed in the periphery
(immune cells) and the central nervous system in non-
neuronal cells (microglia), they represent attractive targets
for the treatment of chronic pain. In fact, they are devoid
of the classic cannabinoid psychotropic side effects (seda-
tion, motor impairment, catalepsy, etc.) while possessing
antinociceptive effects in rodent models even when admin-
istered intrathecally.18,19 Based on preclinical models, the
major mechanism of action of CB2 receptor agonists is
the regulation of immune and inflammatory effectors to
promote a homeostatic local milieu. Therefore, the use of
selective CB2 agonists to target peripherally restricted cells
would effectively modulate pro-nociceptive and pro-
inflammatory effectors that could result in the treatment
of local inflammation, promote tissue repair, and therefore
prevent the development of chronic ulcers or chronic pain.
Immune cells have shown to be valid targets for
the modulation of the local immune response in inflam-
matory conditions since they are the major sources of
inflammatory products, and they express CB2 receptors.
However, inflammation is a dynamic and complex pro-
cess in which various types of immune cells act differ-
ently and at different times of the process.20 This rather
ever-changing inflammatory milieu could represent a
challenge for the identification of the proper time
window and the specific cell target to develop appropri-
ate therapeutic approaches.
Peripheral cells, such as skin cells, not only have struc-
tural purposes but also play a critical role in the modu-
lation of inflammation, tissue repair, and pain. For
example, it has been demonstrated that keratinocytes
are capable of evoking neuronal firing by the production
of neuroactivators which could result in neuroinflamma-
tory states or pain.21 On the other hand, it has been
shown that keratinocytes release b-endorphins via CB2
receptors, which results in the reduction of pain-related
behaviors or endothelin-B receptor activation.22 The
external injection of a pro-algesic factor such as sub-
stance P into the rat hind paw induces an increase of
nerve growth factor (NGF) in epidermal keratinocytes,
which also increases the neuronal hyperexcitability.23
Moreover, keratinocyte biopsies from human subjects
with painful conditions such as complex regional pain
syndrome type 1 (CRPS) or post-herpetic neuralgia
showed a greater expression of sodium channels, which
may contribute to the promotion and maintenance of
pain.24 Fibroblasts also play a role in pain, tissue repair,
or inflammation. In rheumatoid arthritis, they promote
leukocyte infiltration into the joints.25 Moreover, an
impairment in fibroblast growth can impair the proper
wound closure.26 Fibroblasts are also important in the
transition from acute to chronic inflammation.27,28 Due
to the prominent role of keratinocytes and fibroblasts in
inflammation, wound healing, and pain disorders, they
are suitable targets as first responders of the inflammatory
cascade following tissue damage. Since these skin cells
express CB2 receptors,29,30 they represent ideal targets
for selective CB2 receptor agonists for inflammatory
conditions.31
We hypothesize that the preferential activation of
CB2 receptors will promote an anti-inflammatory pheno-
type in human primary keratinocytes and fibroblasts. To
test our hypothesis, we first determined the suitability of
keratinocytes and fibroblasts stimulated with lipopoly-
saccharide (LPS) to be treated with a CB2 receptor agon-
ist by determining the expression of CB1 and CB2
receptors; second, we studied the immune capabilities
of these cells by measuring production of pro- and
anti-inflammatory effectors upon LPS stimulation;
third, we studied the anti-inflammatory effects of
JWH015 ((2-Methyl-1-propyl-1H-indol-3-yl)-1-naphtha-
lenylmethanone), a preferential CB2 receptor agonist, in
these cells by measuring its effects on the production of
pro- and anti-inflammatory products; fourth, we tested
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the CB2 receptor specificity of JWH015’s effects by using
AM630 or AM281 (selective CB2 and CB1 receptor
antagonists/inverse agonists, respectively); fifth, we stu-
died the potential effects of JWH015 in tissue repair by
measuring wound healing capabilities of keratinocytes
and fibroblasts using an in vitro scratch assay; and
sixth, we determine the suitability of JWH015 to reach
keratinocytes and fibroblasts when applied to the skin by
measuring its topical and transdermal penetration in an
ex vivo model.
Materials and methods
Cell culture
Human primary dermal fibroblasts (fibroblasts) were
cultured in Dublecco’s Modified Eagle Medium F12
medium (DMEM-F12, 1) supplemented with 10%
fetal bovine serum (FBS) and 1% penicillin/streptomycin
(Gibco-Life Technologies, Grand Island, NY). Human
primary epidermal keratinocytes (keratinocytes) were
cultured in Dermal Cell Basal Medium supplemented
with a keratinocyte growth kit that contained 0.4%
(v/v) bovine pituitary extract, recombinant human
tumor necrosis growth factor alpha (0.5 ng/mL), L-glu-
tamine (6mM), hydrocortisone hemisuccinate (100 ng/
mL), recombinant human insulin (5 mg/mL), epinephrine
(1 mM), and apo-transferrin (5mg/mL) (Keratinocyte
growth kit, ATCC, Manassas, VA). Keratinocytes or
fibroblasts were generously gifted by Dr. Kim Creek
(University of South Carolina, Columbia). These cells
were obtained from human neonatal foreskin following
circumcision from tissue that is routinely discarded with
no protected health information linked to these samples
and under the IRB protocol PHA IRB #2008-10
(Palmetto Health Institutional Review Board). Both
cell types were plated in 75 cm2 tissue flasks and incu-
bated at 37C in a 5% CO2 atmosphere throughout the
experiment. Media were changed every four to five days.
We ceased use of cells after three passages. Cells were
used when 100% confluence was reached. Cells were
detached by adding 8mL of trypsin/ethylenediaminete-
traacetic acid (EDTA) to the flask for 5min and incu-
bated at 37C in a 5% CO2. The reaction was stopped
with 500 mL of non-diluted FBS. Cells were counted and
plated at the following concentrations: 100,000 cells/mL/
well for keratinocytes when cultured alone and 100,000
cells/mL/well for fibroblasts when cultured alone. For
scratch assays, cells were plated together in a co-culture
containing 50,000 cells/mL of fibroblasts and 50,000
cells/mL of keratinocytes. Subsequently, the cells were
incubated for 24 h in all cases before the addition of
LPS stimulation and/or any pharmacological treatment.
At this point, the media were changed and LPS was
added with or without any pharmacological treatment,
depending on the experimental paradigm. Each cell cul-
ture/experiment was performed using cells from one or
two different independent donors. We performed the fol-
lowing experimental paradigms.
Experimental paradigm 1. This experiment was conducted
to determine the time course of cytokine secretion by
keratinocytes or fibroblasts after a challenge with LPS.
Keratinocytes were stimulated with 10 mg/mL LPS, and
fibroblasts were stimulated with 5 mg/mL LPS. LPS and
its concentration were chosen, based on the literature
and on our previous pilot experiments, in order to stimu-
late the cells.32,33 LPS was dissolved in sterile distilled
water (Escherichia coli O111:B4; Sigma Aldrich, St.
Louis, MO). Supernatants were collected at 4, 24, 48,
72 and 96 h following the LPS challenge. Supernatants
under these conditions were frozen at 80C until cyto-
kine assays.
Experimental paradigm 2. This experiment was conducted
to determine the potency and efficacy of JWH015 in the
production of pro- and/or anti-inflammatory factors by
keratinocytes and fibroblasts. We constructed JWH015
dose–response curves using the following concentrations:
0.05, 0.1, 0.5 and 1 mM (dissolved JWH015 in 0.1%
DMSO, to total 1mL). JWH015 and LPS were added
to the culture concomitantly (time 0). These studies were
performed at a given time following LPS stimulation,
and an incubation time point was chosen based on the
first experimental design (24 h). Supernatants under these
conditions were collected at the chosen time point and
frozen at 80C until pro- and anti-inflammatory prod-
ucts were measured.
Experimental paradigm 3. This experiment was conducted
to determine whether JWH015’s effects on pro- and/or
anti-inflammatory products in keratinocytes or fibro-
blasts were exerted through CB1 and/or CB2 receptor
activation. We aimed to block JWH015’s effects with
either the CB1 receptor antagonist/inverse agonist,
AM281, or the CB2 receptor antagonist/inverse agonist,
AM630 (dissolved in 0.2% DMSO, to total 1mL for
both AM218 and AM630). For either AM281 or
AM630, a concentration of 1 mM was utilized, which is
equivalent to the most effective concentration tested for
JWH015. We have previously demonstrated that AM281
and AM630 at this concentration display an acceptable
level of specificity for CB1 (AM281) and CB2 (AM630)
receptors in in vitro cell cultures.13 The antagonist/
inverse agonist, LPS, and JWH015 were added to the
culture concomitantly (time 0).
These studies were performed at a given time follow-
ing LPS stimulation, and an incubation time point
was chosen based on the first experimental design
(24 h). We chose a given JWH015 concentration based
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on the second experimental design (1 mM). Supernatants
under these conditions were collected at the chosen time
point and frozen at80C until pro- and anti-inflammatory
products were measured.
Enzyme-linked immunosorbent sandwich
assay analyses
The supernatant concentration of interleukin-6 (IL-6),
monocyte chemoattractant protein-1 (MCP-1), trans-
forming growth factor-beta (TGF-b), tumor necrosis
factor-alpha (TNF-a), and IL-10 was measured with
commercial enzyme-linked immunosorbent sandwich
assay (ELISA) kits (human IL-6, human MCP-1,
human TGF-b, human TNF-a, and human IL-10
ELISA Ready-SET-Go!; eBioscience, San Diego, CA).
Sensitivity of the ELISA kits is as follows: 2 pg/mL for
human IL-6 and IL-10, 8 pg/mL for MCP-1, and TGF-b,
4 pg/mL for TNF-a. These assays were performed fol-
lowing the manufacturer’s instructions.
RNA isolation and quantitative RT-PCR
Cannabinoid receptor types 1 and 2 mRNA was deter-
mined 24 h following LPS stimulation in keratinocytes or
fibroblasts. This time point was chosen based on the first
experimental paradigm, described previously. Following
cell incubation, the cells were washed with 1mL of ice-
cold sterile PBS, collected using BLþTG buffer (PBS
and 1-thioglycerol), and stored at 80C until RNA iso-
lation experiments. RNA was isolated from both types of
cells using Reliaprep RNA Cell Miniprep System
(Promega, Madison, WI) according to manufacturer’s
protocols.
The levels of mRNA were determined as described
previously.34 Briefly, 1 mg of total RNA from each
sample was reverse transcribed into cDNA using Script
Reverse Transcription Supermix (BioRad, Hercules) in
the following conditions: 5min at 25C, 30min at 42C,
and 5min at 85C. We quantified the expression of CB1
(57C), CB2 (57C), and b-actin (57C) using
SsoAdvanced Universal SYBR Green Supermix
(BioRad, Hercules, CA) in the following conditions: 1
cycle of 98C for 30 s, 45 cycles of 98C for 15 s, 30 s of
the primer-specific annealing temperature. The primers
for real-time (RT)-PCR are shown in the Supplementary
Table 1. All samples were run in duplicate using the
CFX96 Real-Time PCR system (Bio-rad, Hercules). A
melt curve analysis was performed between 65C and
95C in 0.5 intervals (5 s per interval). The expression
of mRNA for our molecules of interest was normalized
to the b-actin expression level. Then, the fold change of
the cannabinoid receptors was calculated using the
values of non-stimulated cells (control), which was
given a value equal to 1. The fold change of each gene
was determined using the ddCt method, as previously
described.35
Scratch assay
This in vitro assay is widely used to study some func-
tional aspects of keratinocytes and fibroblasts in the
wound healing process.36–38 We conducted this experi-
ment to determine whether the immunomodulatory
effects of JWH015 on keratinocytes and fibroblasts
affect their migration capabilities.
Keratinocytes and fibroblasts were cultured individu-
ally, as described previously, and co-cultured in Dermal
Cell Basal Medium for 24h at 37C in 5% CO2. The
scratch was created in the cell monolayer using a 10mL
pipette tip. To make the scratch a consistent size, and to
allow further imaging follow-up, two marks were made at
the bottom of each well. The scratch was made between
these marks in all cases. The cellular debris was removed
(by replacing the media) then an LPS stimulus (10mg/mL)
and the pharmacological treatment were added when
appropriate. The following groups were used: keratino-
cytes and fibroblasts stimulated with LPS in the presence
or the absence of JWH015 (1mM, 0.2% DMSO in PBS),
keratinocytes and fibroblasts stimulated with LPS and
JWH015 (1mM, 0.2% DMSO in PBS) in the presence
or in the absence of AM281 (CB1 receptor antagonist/
inverse agonist, 1mM, 0.2% DMSO in PBS) or AM630
(CB2 receptor antagonist/inverse agonist, 1mM, 0.2%
DMSO in PBS).
The migration capabilities of these cells to fill the
scratch gap mimic a wound healing process.36,37 This
process was measured at base line (0 h), and at 4, 12,
17 and 24 h following the scratch. Six digital images
(5) per condition were taken at each time point in the
same area, next to a line of reference that was drawn
previously. Digital images were taken using a digital
camera attached to a microscope (Leica Microscope
Imaging Software, Leica Microsystems, Buffalo Grove,
IL). These images were processed with SigmaScan Pro
software (Systat Software Inc., San Jose, CA). For each
picture, the remaining gap of the scratch was masked,
and the number of pixels in that area was recorded.
Thus, the scratch gap at time 0 produced a consistently
higher number of pixels. The average value obtained for
the six images was used to determine the gap value of
each observation (six observations were made per
group). The values obtained in each condition were nor-
malized with their respective baseline values at time 0, to
control for baseline variations.
Synthesis of compound JWH015
To test the pro- and anti-inflammatory effects of a CB2
agonist, we utilized a commercially available formulation
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of JWH015 (Tocris Biosience, 155471-08-2, Ellisville,
MO). Our purpose was to identify whether CB2 receptor
agonists directly affect the functionality of keratino-
cytes and fibroblasts under inflammatory conditions.
Therefore, a minimal transdermal penetration and/or a
potential lipid depot effect formation were desirable. For
our transdermal experiments, we synthesized JWH015 to
provide the quantities that are needed for transdermal
and topical testing.
The synthesis of JWH015 was performed in-house
according to the combined, modified procedures of and
Huffman and Dai39 and Bell et al.40 Briefly, 2-methylindole
was N-propyl-substituted under strong, basic conditions
using 1-bromopropane to afford the intermediate,
2-methyl-1-propylindole (Supplementary Figure 1). The
reaction mixture was purified by TLC grade flash chro-
matography (1:19 ethyl acetate/hexanes) and the inter-
mediate carried forward to the proceeding synthetic step.
The compound 2-methyl-1-propylindole was converted
to JWH015 through the addition of 1-naphthoyl chloride
under the appropriate Friedel-Crafts acylation condi-
tions. The reaction mixture was purified by TLC grade
silica gel flash chromatography (1:24 ethyl acetate/
toluene) and structurally characterized via 1H nuclear
magnetic resonance spectroscopy (NMR). The NMR
signals were identical to the published values, and
no impurities were detected. Elemental analysis of
JWH015 met the American Chemical Society standards
for purity (Anal. Calcd for C23H21NO: C, 84.37; H, 6.46;
N, 4.28. Found: C, 84.25; H, 6.54; N, 4.23). The final
product in the free base form was a clear to light straw
colored viscous oil that appeared to demonstrate chem-
ical instability upon exposure to light and/or air.
Samples were stored in the dark at 20C under nitrogen
conditions following purification until the time of use.
Ex vivo JWH015 skin permeability studies
The transdermal absorption of JWH015 was studied
utilizing porcine skin obtained from an abattoir
(Thompson’s Meat Market, Alexandria, AL). Modified
Franz diffusion cells (diffusional area: 0.64 cm2; receptor
volume: 5.1mL; Permegear Inc., Riegelsville, PA) were
used as described previously.41 The receptor chamber
was filled with isotonic PBS at a pH of 7.4, maintained
at 37C 0.5C, and continuously stirred at 600 r/min.
Fresh porcine skin was secured in each of the diffusion cells
and was allowed to equilibrate for 30 min, while bathed in
PBS. Following equilibration, approximately 0.5 mL of the
respective formulation was placed on each cell.
The samples of porcine skin were incubated with
either 0.5mL of mineral oil containing 5% JWH015 or
0.5mL of the control vehicle containing mineral oil only.
The samples (300mL) were taken from the receptor
chamber at 0.5, 1, 2, 3, 4, 5, 6, 12, and 24 h.
The volume of each sample was immediately replaced
with fresh PBS following sample collection, as described
previously.41 Samples were stored at 80C until further
analysis. The samples were analyzed using liquid chro-
matography-mass spectrometry (LC-MS). The drug con-
centration was measured and represented as mg/cm2.41
Porcine skin extractions of JWH015
After the 24-h time point in the skin permeability studies,
the porcine skin was collected to determine the amount
of drug present in each of the skin samples. The mass of
the porcine skin portion that was exposed to the formu-
lation was resected, washed, and weight recorded.
The skin was then dissected and diluted with dichloro-
methane at a ratio of 1 g:10mL. An OmniTHQ Digital
Tissue Homogenizer (Omni International, Kennesaw,
GA) was used to homogenize each skin sample. After
being mixed, 1mL of supernatant was placed in an
Eppendorf tube and centrifuged at 11,000 r/min for
30min (Fisher Scientific AccuSpin Micro 17, Germany).
The supernatant was collected and frozen at 80C for
further LC-MS analysis. The drug concentration was
measured and represented as mg/g.42
LC-MS analysis of JWH015 for transdermal samples
All transdermal samples were spiked with 100 mL of an
approximately 2.5 ppb solution of deuterium-labeled
internal standard (JWH015-d7) obtained from Cayman
Chemical Co (Ann Arbor, MI). Samples were then
quantitatively transferred to LC autosampler vials and
capped. Standards were prepared with concentrations
ranging from 0.2 ppb to 10 ppb. Each standard solution
was spiked with 100 mL of the deuterium-labeled internal
standard, mentioned above.
The following are the parameters used for the LC ana-
lyses: Waters Acquity Classic binary pump; Column:
Chromegabond WR C18 3mm particles 15 cm 2.1mm
(ES Industries, West Berlin, NJ); Gradient: Solvent A:
Water with 0.1% formic acid; Solvent B: Acetonitrile
with 0.1% formic acid; Flow rate: 200mL/min. The time
and composition used are as follows: 0min, 25% B; 2min,
25% B; 15min, 100% B; 20min, 100% B; 20.1min,
25% B.
The following are the parameters used for the MS
analyses: Waters Quattro Premier XE triple quadupole
mass spectrometer; Ionization: positive ion electrospray.
The desolvation gas flow was set to 700L/h at a tem-
perature of 350C; the cone gas flow was set to 15L/h.
Collision gas was Ar set to 0.25mL/min resulting in a cell
pressure of 3.3 103 mbar. The mass spectrometer was
operated in MRM mode, monitoring two transitions;
one for the analyte 328m/z> 155m/z and one for the
internal standard 335m/z> 155m/z. Each transition
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had a 100ms dwell time with a 50 ms interchannel delay
and a 50 ms interscan delay. A cone voltage of 25 V was
set for both transitions. A collision energy of 20 eV was
used for both analyte and internal standard.
Levels of analyte in each sample were determined
using the internal standard method. A calibration was
generated by injecting three replicates of four standards.
Linear regression with 1/ weighting was used to pro-
duce the calibration curve.
LC-MS analysis of JWH015 for skin samples
All skin samples were blown down to dryness with a
gentle stream of nitrogen and reconstituted in 3mL of
chloroform. Ten microliters of each sample were then
transferred to LC sample vials containing 1.5mL aceto-
nitrile and 200 mL of a 3 ppm internal standard solution.
Standards were prepared with concentrations ranging
from 50 ppb to 1.3 ppm. Each standard was spiked
with 200 mL internal standard as above.
Statistical analysis
All the statistical analyses were performed using
GraphPad Prism 6.01 (GraphPad Software Inc., La
Jolla, CA). Two-tailed unpaired t-tests and one- or
two-way ANOVAs followed by Bonferroni’s or
Dunnett’s post hoc were used as appropriate. A value
of 0.05 was considered as statistically significant. Dose–
response curves were obtained using a non-linear regres-
sion fitting method. The EC50 values were calculated
using normalized-response-variable hill slope function
to the data (Y¼ 100/(1þ 10(LogEC50-X)Hill Slope).
The number of samples per group was based on the min-
imum number of data needed for statistical power (0.80)
and significance (0.05), as determined from previous
similar analyses.
Results
Cannabinoid receptors’ mRNA in LPS-stimulated
fibroblasts and keratinocytes
We determined the baseline expression of cannabinoid
receptors mRNA in keratinocytes and fibroblasts at
24 h and after an LPS challenge. The LPS concentration
we used to produce cell activation was based on the
literature and on our previous pilot experiments.32,33
We used 5 mg/mL of LPS to stimulate fibroblasts,
and 10 mg/mL of LPS to stimulate keratinocytes. We
observed that LPS stimulation produced a significant
up-regulation of CB1 (Figure 1(a)) and CB2 (Figure 1(b))
mRNA in both keratinocytes and fibroblasts, when com-
pared to non-stimulated cells.
Cytokine expression in keratinocytes and fibroblast
after LPS challenge
We measured the cytokine concentration in cultures of
either keratinocytes or fibroblast at different time points
(4, 24, 48, 72 and 96 h) after an LPS challenge to deter-
mine the best time point to test the effects of JWH015.
When we stimulated keratinocytes with 10 mg/mL of
LPS, we found a significant increase in IL-6 from 4 to
96 h after stimulation. The levels of IL-6 peaked at 48 h
and remained at this level 72 and 96 h after LPS stimu-
lation (Figure 2(a)). The levels of MCP-1 produced by
LPS-stimulated keratinocytes significantly increased at
4 h and remained elevated until 96 h after LPS stimula-
tion (Figure 2(b)). The concentration of TGF-b from
Figure 1. Expression of CB1 and CB2 receptors in human keratinocytes or fibroblasts following LPS stimulation. Quantification of CB1
(a) and CB2 (b) mRNA expression in LPS-stimulated keratinocytes or fibroblasts. The gene expression of CB1 or CB2 was normalized to
the respective levels of b-actin in each sample and then calculated as fold change against the control group (non-stimulated cells), which was
assigned a value equal to 1. Data shown are means SD; n¼ 5–6 samples. *P< 0.05 vs. non-stimulated cells using Student’s t-test. LPS:
lipopolysaccharide; CB1: cannabinoid receptor 1; CB2: cannabinoid receptor 2.
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LPS-stimulated keratinocyte culture increased from 24
to 96 h after stimulation, peaking at 48 h (Figure 2(c)).
Fibroblasts that were stimulated with 5 mg/mL of LPS
displayed an increase in IL-6 concentration from 4h to
96 h. The maximum amount of IL-6 in fibroblasts was
found at 24 h after LPS stimulation (Figure 2(d)). The
levels of MCP-1 produced by LPS-stimulated fibroblast
increased from 24 to 96 h and reached its highest concen-
tration at 96 h after LPS stimulation (Figure 2(e)). The
levels of TGF-b produced by LPS-stimulated fibroblasts
significantly increased at 24 h and remained stable until
96 h after LPS stimulation (Figure 2(f)). We did not
detect IL-10 or TNF-a in either keratinocytes or fibro-
blasts; the concentrations of these cytokines were below
the sensitivity level of the ELISA kits used.
Based on these results, we tested the effects of
JWH015 at 24 h after LPS stimulation in both keratino-
cytes and fibroblasts. We decided to test at 24 h of incu-
bation because LPS consistently produced effects in all
the detected cytokines at this time point.
The effects of JWH015 on LPS-stimulated
keratinocytes and fibroblast
Keratinocytes and fibroblasts were stimulated with LPS
and treated, concomitantly, with different concentrations
of either JWH015 (0.05, 0.1, 0.5, and 1 mM) or its vehicle
control (0.1% DMSO in saline) for 24 h. As previously
reported, LPS induced an increase in IL-6, MCP-1, and
TGF-b in both keratinocytes and fibroblast (Figure 3,
gray bars).
When JWH015 was added to LPS-stimulated kera-
tinocytes, we observed a significant decrease in IL-6
(Figure 3(a)). The percent effect curve of JWH015 for
IL-6 concentration in keratinocytes is displayed in
Figure 4(a).
When JWH015 was added to LPS-stimulated kera-
tinocytes, we observed a significant decrease in MCP-1.
This effect was concentration dependent (Figure 3(b)).
The percent effect curve of JWH015 for MCP-1 concen-
tration in keratinocytes is displayed in Figure 4(b).
Keratinocytes stimulated with LPS and, concomi-
tantly, treated with JWH015 displayed elevated levels
of TGF-b compared to the vehicle control group. This
effect was concentration dependent (Figure 3(c)) and
consistent with an anti-inflammatory effect. The percent
effect curve of JWH015 for TGF-b concentration in
keratinocytes is displayed in Figure 4(c). The minimum
effective dose, efficacy, and potency of JWH015 for all
these factors in keratinocytes are displayed in Table 1.
We determined that the addition of LPS alone
(87.95 1.8% of viable cells) or LPS with JWH015
(88.9 1.3% of viable cells) did not produce any signifi-
cant cytotoxicity in keratinocytes when compared to
non-stimulated cells (92.2 1.8% of viable cells).
Fibroblasts stimulated with LPS and treated with
JWH015 for 24 h exhibited a concentration-dependent
decrease in IL-6 (Figure 3(d)). The percent effect curve
of JWH015 for IL-6 concentration in keratinocytes is
displayed in Figure 4(d).
When JWH015 was added to LPS-stimulated fibro-
blasts, we observed a significant, concentration-dependent
Figure 2. Effect of LPS in cytokine concentration in primary human fibroblast or keratinocyte cultures. Quantification of IL-6 (a and d),
MCP-1 (b and e) and TGF-b (c and f) from supernatants of keratinocytes or fibroblasts (respectively) stimulated with LPS (10 and 5 mg/mL,
respectively). Each bar represents the mean SD of 6 samples. *P< 0.05 vs. 0 h by using One-way ANOVA followed by Dunnett’s post hoc
test. LPS: lipopolysaccharide; IL-6: interleukin-6; MCP-1: monocyte chemoattractant protein-1; TGF-b: transforming growth factor-beta.
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decrease in MCP-1 (Figure 3(e)). The percent effect curve
of JWH015 for MCP-1 concentration in keratinocytes is
displayed in Figure 4(e).
Fibroblasts stimulated with LPS and, concomitantly,
treated with 1 mM of JWH015 displayed an increase of
TGF-b (Figure 3(f)). The percent effect curve of JWH015
for TGF-b concentration in keratinocytes is displayed in
Figure 4(f). The minimum effective dose, efficacy, and
potency of JWH015 for all these factors in fibroblasts
are displayed in Table 1.
We determined that the addition of LPS alone (88.1
2.1% of viable cells) or LPS with JWH015 (86.9 5.5%
of viable cells) did not produce any significant cytotox-
icity in fibroblasts when compared to non-stimulated
cells (92.3 1.7% of viable cells).
Based on these results, we decided to use 1 mM of
JWH015 to test the involvement of CB1 and CB2 recep-
tors on the effects of JWH015.
Blockade of JWH015’s effects using CB1 and CB2
antagonist/inverse agonists
Keratinocytes or fibroblasts were stimulated with LPS
and concomitantly incubated with JWH015 (1 mM)
alone, JWH015 (1 mM)þAM281 (1 mM), or JWH015
(1 mM)þAM630 (1 mM). Cytokine release was 24 h
after the addition of the drugs, since JWH015 consist-
ently produced an anti-inflammatory phenotype at this
time point. As previously shown, we observed that the
addition of LPS increased the concentration of IL-6,
MCP-1, and TGF-b in both keratinocytes and fibro-
blasts incubated for 24 h (gray bars, Figure 5).
The concentration of IL-6 was significantly reduced
by the addition of JWH015 to LPS-stimulated keratino-
cytes. This effect of JWH015 on IL-6 was completely
blocked by AM630, and partially blocked by AM281
(CB2 and CB1 antagonist/inverse agonist, respectively;
Figure 5(a)). Similarly, the concentration of MCP-1
was significantly decreased by JWH015 when added to
LPS-stimulated keratinocytes, as described before. This
decrease of MCP-1 induced by JWH015 was blocked by
AM630 (CB2 antagonist/inverse agonist), but not by
AM281 (CB1 antagonist/inverse agonist; Figure 5(b)).
The addition of JWH015 to LPS-stimulated keratinocytes
increased the concentration of TGF-b, as previously
shown, and this effect was blocked by either AM630 or
AM281 antagonists/inverse agonists (Figure 5(c)).
The concentration of IL-6 was significantly reduced
by the addition of JWH015 to LPS-stimulated fibro-
blasts. This effect of JWH015 on IL-6 was completely
Figure 3. Effects of JWH015 in cytokines produced by keratinocytes or fibroblasts challenged with LPS. Quantification of IL-6 (a and d),
MCP-1 (b and e) and TGF-b (c and f) in keratinocytes or fibroblasts (respectively) stimulated with LPS (10 and 5mg/mL, respectively) for
24 h and treated with increasing concentrations of JWH015. Each bar represents the mean SD of 6 samples. #P< 0.05 vs. non-stimulated
cells, þP< 0.05 vs. control group (LPSþ vehicle) using One-way ANOVA followed by Dunnett’s post hoc test. *P< 0.05 between con-
nected groups using One-way ANOVA followed by Tukey’s post hoc test. Lipopolysaccharide; IL-6: interleukin-6; MCP-1: monocyte
chemoattractant protein-1; TGF-b: transforming growth factor-beta.
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blocked by AM630 or AM281 antagonists/inverse agon-
ists (Figure 5(d)). Similarly, the concentration of MCP-1
was significantly decreased by JWH015 when added to
LPS-stimulated fibroblasts. This decrease of MCP-1
induced by JWH015 was blocked by either AM630 or
AM281 antagonists/inverse agonists (Figure 5(e)). The
addition of JWH015 to LPS-stimulated fibroblasts
increased the concentration of TGF-b, as previously
shown, and this effect was blocked by either AM630 or
AM281 antagonists/inverse agonists (Figure 5(f)).
These findings suggest that the effects of JWH015 are
mainly mediated by CB1 and CB2 receptors, except for
the decrease of MCP-1 in keratinocyte that is predomin-
antly induced via CB2 receptors.
Effects of JWH015 in an in vitro model of wound
healing
Given that JWH015 showed a prominent anti-inflamma-
tory effect, and, specifically, induced an increase in TGF-b
Figure 4. Percent of the effect of JWH015 in cytokines produced by keratinocytes or fibroblasts challenged with LPS. Concentration-
response curves for IL-6 (a and d), MCP-1 (b and e) and TGF-b (c and f) in keratinocytes or fibroblasts (respectively) stimulated with LPS
(10 and 5 mg/mL, respectively) for 24 h and treated with JWH015. Each bar represents the mean SD of 6 samples. LPS: lipopolysaccharide;
IL-6: interleukin-6; MCP-1: monocyte chemoattractant protein-1; TGF-b: transforming growth factor-beta.
Table 1. Effective concentration 50 (EC50), percentage of efficacy and minimum effective concentration
(MEC) of JWH015 in keratinocytes and fibroblast stimulated with LPS.
EC50 (mM) Efficacy (%) MEC (mM)
Cytokine Keratinocytes Fibroblasts Keratinocytes Fibroblasts Keratinocytes Fibroblasts
IL-6 1.02 0.01 0.66 0.08 56.67 10.63 58.9 7.61 1 0.5
MPC-1 1.86 0.04 1.24 0.04 31.61 5.99 45.84 3.84 0.5 0.1
TGF-b 0.19 0.17 0.60 0.02 66.56 14.64 54.62 17.15 1 1
Note: For the conditions in which the 50% effect of JWH015 was not completely reached the EC50 was calculated by
extrapolation. EC50: effective concentration 50; MEC: minimum effective concentration; IL-6: interleukin-6; MCP-1:
monocyte chemoattractant protein-1; TGF-b: transforming growth factor-beta.
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(a well-documented pro-wound healing factor), we inves-
tigated whether JWH015 plays any role in the scratch
assay model (in vitro) of wound healing. The co-culture
of fibroblasts and keratinocytes was challenged with
10mg/mL of LPS and, concomitantly, exposed to the
following conditions: LPSþ vehicle (0.2% DMSO in
PBS), LPSþ 1mM of JWH015 alone, LPSþ 1mM of
JWH015þ 1mM of AM281 (CB1 antagonist/inverse
agonist), and LPSþ 1mM of JWH015þ 1mM of
AM630 (CB2 antagonist/inverse agonist). All data were
normalized to the control time point for all groups, 0 h, to
control for baseline variations and the percent of gap clos-
ure was determined. In unpublished data, we have
observed that the gap closure of the scratch in kera-
tinocytes and fibroblasts in co-culture is approximately
23–45% at 17 and 19h (preliminary data).
We observed that the scratch in keratinocytes and
fibroblasts in co-culture was 24–27% closed in the
LPSþ vehicle group at 17 - and 24-h time points, respect-
ively. When JWH015 and LPS were simultaneously
added to the co-culture, the scratch gap was 36–40%
closed at 17 - and 24-h time points, respectively
(Figure 6). Interestingly, the addition of JWH015 to
the co-culture wound produced a faster and more
efficient closure of the scratch width when compared
with the LPS control group at 12, 17, and 24 h after
LPS addition (Figure 7). Either AM281 or AM630
blocked this effect produced by JWH015 at 12, 17, and
24 h after the scratch (Figure 7). These findings suggest
that the wound healing effects, as many of the cytokine
modulation, induced by JWH015 in the scratch assay
model is modulated via CB1 and CB2 receptors.
We determined that the addition of LPS alone
(88.3 1.1% of viable cells) or LPS with JWH015
(91.7 2.3% of viable cells) did not produce any sig-
nificant cytotoxicity in co-cultured keratinocytes and
fibroblasts when compared to non-stimulated cells
(91.6 1.2% of viable cells).
Transdermal and topical delivery of JWH015
in porcine skin
We determined the ability of JWH015 to reach keratino-
cytes and fibroblasts when applied to the skin by measur-
ing its topical and transdermal penetration in an ex vivo
porcine skin model.
The samples of porcine skin were incubated with
0.5mL of mineral oil containing 5% JWH015 or
Figure 5. Blockade of JWH015’s effects in cytokines produced by keratinocytes or fibroblasts by CB1 or CB2 receptor antagonist/
inverse agonist. Concentrations of IL-6 (a and d), MCP-1 (b and e) and TGF-b (c and f) in keratinocytes or fibroblast (respectively)
stimulated with LPS (10 and 5mg/mL, respectively) and concomitantly incubated with 1 mM of JWH015 alone, JWH015
(1mM)þAM281 (1mM, CB1 antagonist/inverse agonist) or, JWH015 (1mM)þAM630 (1 mM, CB2 antagonist/inverse agonist). Each bar
represents the mean SD of six samples. #P< 0.05 vs. non-stimulated cells, þP< 0.05 vs. control group (LPSþ vehicle) using One-
way ANOVA followed by Dunnett’s post hoc test. *P< 0.05 between connected groups using One-way ANOVA followed by Tukey’s
post hoc test. LPS: lipopolysaccharide; IL-6: interleukin-6; MCP-1: monocyte chemoattractant protein-1; TGF-b: transforming growth
factor-beta.
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0.5mL control vehicle containing mineral oil only. The
samples were taken at 0, 0.5, 1, 2, 3, 4, 5, 6, 12 and 24 h
after the addition of the drug. The samples were ana-
lyzed by LC-MS to detect the amount of JWH015 that
had passed through the skin to reach the receptor com-
partment. The transdermal concentration (delivery) of
JWH015 was only significantly higher at 3 h, the time
in which the transdermal concentration of JWH015
peaked in our system (73.62 0.05 ng/cm2). The trans-
dermal JWH015 concentrations were not significantly
different at any other time point tested, and remained
lower than 34.92 0.04 ng/cm2 (Figure 8).
We evaluated the retention of JWH015 in porcine skin
24 h after its topical delivery. High levels of the drug
were retained in the skin tissue under our conditions.
The average tissue concentration of JWH015 was
881 191mg/g in the drug-treated tissues, which was
significantly higher in comparison to the control (vehicle)
group (Figure 9).
Discussion
The major findings of our studies are: (1) The addition of
an inflammatory stimulus (i.e. LPS) to primary human
keratinocytes and fibroblasts induced an increase in the
expression of CB1 and CB2 receptors at the mRNA
level; (2) JWH015 reduced the concentration of major
pro-inflammatory factors (i.e. IL-6 and MCP-1) and
enhanced the concentration of a major anti-inflamma-
tory factor (i.e. TGF-b) in primary human keratinocyte
and fibroblast cultures; (3) JWH015 induced a more
efficient in vitro wound healing process in primary
human keratinocytes and fibroblasts co-cultures; (4) the
immunomodulatory and pro-wound healing effects of
JWH015 were promoted mostly through both CB1 and
CB2 receptors; and (5) JWH015 administered transder-
mally is mostly retained in the skin and displays a sus-
tained and low transdermal distribution. Our findings
offer data that support the use of cannabinoids to
Figure 6. Representative photomicrographs showing the wound closure time course. The scratch assay was performed in LPS-stimulated
keratinocytes and fibroblast co-cultures in the presence or the absence of JWH015 (1 mM) with or without a CB1 (AM281, 1mM) or CB2
(AM630, 1mM) antagonist/inverse agonist.
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target skin cells for the treatment of peripheral inflam-
matory conditions.
In accordance with previous observations in keratino-
cytes43 and fibroblasts,44 our data indicate that the
cannabinoid system in skin cells is positively regulated
on demand (under pathological conditions), as it has
been described in other systems.13,45,46 Therefore, canna-
binoid receptors in keratinocytes and fibroblasts are suit-
able targets under pathological inflammatory conditions.
The immunomodulatory effects displayed by JWH015
in human keratinocytes and fibroblasts are in line with its
effects on cytokine production in other cells of the
immune system, such as macrophages,47 lymphocytes,48
or microglia.13 The reduction of IL-6 and IL-8 by can-
nabinoid receptor activation has been previously shown
in human synovial-like fibroblasts stimulated with IL-1b
using non-selective cannabinoids.29 These compounds
have been associated in vivo with psychotropic side
effects.49,50 Similarly, anandamide (AEA) decreases
MCP-1, IL-6, and IL-8 in LPS-stimulated gingival fibro-
blasts and those effects are mediated by both CB1 and
CB2 receptors.44 JWH015, which is a relatively low
potency preferential CB2 agonist with a Ki of 13.8 nM
for CB2 and 383 nM for CB1, has been shown to be
effective in reducing pain-related behaviors and modulat-
ing inflammatory responses in the spinal cord without
inducing psychotropic effects even when administered
intrathecally.18,19 These data together suggest that can-
nabinoids with relatively low potency (at least through
CB1 receptors) are devoid of the central side effects asso-
ciated with potent cannabinoids; yet, this low potency is
sufficient to induce an anti-inflammatory phenotype in
skin cells.
All these pro- and anti-inflammatory factors are piv-
otal in the generation and resolution of inflammation
and tissue repair in a variety of inflammatory or painful
conditions. Interleukin-6 is quickly detected in response
to injury and its increase is correlated with the degree of
tissue damage.51 Increased IL-6 levels have been reported
following surgeries and burns and are correlated with
the development of postoperative pain.52–54 Likewise,
MCP-1 release is increased in the early stages of tissue
repair after injury55 and exerts its main effects through
Figure 7. Effect of JWH015 in the in vitro scratch assay.
Quantification of gap closure represented as percentage in a
wounded (scratch) co-culture of keratinocytes and fibroblast in the
presence or the absence of LPS (10 and 5 mg/mL, respectively) and
with LPS with 1 mM of JWH015 with or without a CB1 (AM281) or
CB2 (AM630) antagonist/inverse agonist. Data shown are
means SD; n¼ 5–6 samples.þ P< 0.05 vs. control group
(LPSþ vehicle), *P< 0.05 vs. LPSþ JW015 using Two-way ANOVA
with repeated measures followed by Tukey’s post hoc test. LPS:
lipopolysaccharide.
Figure 8. Transdermal delivery of JWH015 in an ex vivo model.
Quantification of JWH015 by from samples taken at 0, 0.5, 1, 2, 3,
4, 5, 6, 12 and 24 h after the addition of JWH015 or vehicle on pig
skin tissue mounted in Franz cells. Data shown are means SD;
n¼ 5 samples. *P< 0.05 vs. 0 h using One-way ANOVA followed
by Dunnett’s post hoc test.
Figure 9. Retention of JWH015 on pig tissue. Quantification of
JWH015 in pig skin tissues incubated with JWH015 for 24. Data
shown are means SD; n¼ 3–6 samples. *P< 0.05 vs. vehicle
using Student’s t-test.
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the recruitment of cells to the site of the injury.56 MCP-1
has an important role in early stages of the healing
process,55,57 and it is correlated with pain in patients
with temporomandibular disorders58 and fibromyalgia.59
Peripheral MCP-1 is important in a mice model of
chronic neuropathic pain.60
Keratinocytes and fibroblasts are also able to produce
pro-wound healing factors, such as TGF-b. This anti-
inflammatory molecule mediates the restoration of
homeostasis following tissue injury61,62 and is necessary
for proper wound healing.63 Interestingly, the local
administration of recombinant TGF-b into mouse hind
paws reduces mechanical hyperalgesia in a murine model
of neuropathic pain.64 Our findings indicate that the
increase in TGF-b from skin cells induced by JWH015
could explain at least in part the improved wound heal-
ing process observed in our studies. Accordingly, the
activation of both CB1 and CB2 receptors has been
shown to improve the wound closure in the scratch
assay using single cell cultures of human gingival fibro-
blasts.65 Furthermore, it seems that the activation of
CB2 receptors reduces the fibrotic formation in a
wound model in mice through the modulation of TGF-
b in late stages of the wound healing process.66 This anti-
fibrotic effect mediated by CB2 receptor activation has
been confirmed in CB2 receptor knockout mice studies.67
On the other hand, CB1 receptors activation promotes a
fibrotic response in mice.68 In fact, it seems that CB1 and
CB2 receptors possess opposite effects in some skin cell
functions, such as in epidermal permeability in a mouse
model.69
These data together suggest that the activation of can-
nabinoid receptors in skin cells may be particularly
attractive to modulate the inflammatory process,
reduce pain and promote a more efficient tissue repair
in post-surgical or post-burn conditions.
JWH015 or other cannabinoids display differential
receptor dependence for the modulation of different cel-
lular functions.13,19,30,47,48 However, it is clear that the
effects of JWH015 at concentrations 41 mM in human
skin cells are anti-inflammatory and non-selective to CB1
or CB2 receptors, while its effects in macrophages,
lymphocytes, and the CNS (at least in rodents) seem to
be mediated mainly via CB2 receptors. This intriguing
feature could represent an advantageous property for
this type of compounds since a dual CB1/2 receptor
activity could provide a wider spectrum of beneficial
effects in skin cells when administered locally, while
they will be devoid of CB1-dependent central side effects
if they reach systemic and central distribution.
Peripheral administered therapies are getting increas-
ing attention for conditions with predominantly periph-
eral inflammatory mechanisms, such as psoriasis,
arthritis, postoperative pain, burns, etc. Most of the
attention has been paid to the modulation of peripheral
immune cells. However, there is mounting evidence that
demonstrates skin cells could play a prominent role in
many states with peripheral inflammation. Since these
cells are readily accessible, they represent ideal drug
targets, as demonstrated in our topical/transdermal ex
vivo system. Whereas hydrophobic and macromolecules
are poorly permeable to skin, lipophilic compounds pos-
sess a better profile for topical or transdermal delivery.
Using our ex vivo system, we determined the high logP
of JWH015 to be 5.18, as predicted by ChemDraw
Software (Perkin Elmer, Wlatham, MA), confirming
the hydrophobic nature of the compound. This is in
agreement with the low amount of JWH015 that
passed across the flow-through diffusion cell system
and the high concentrations of the compound that was
retained in the skin. This is in accordance with other
drugs with high logP (fentanyl, logP 4.05) that form a
depot in skin.70 In our system, we used porcine skin,
which has been extensively used for transdermal delivery
studies for other drugs due to the similarities to human
skin with regard to lipid composition and subcutane-
ous fat content.42,71 It has been shown that intact
human skin (stratum corneum) exhibits a certain level
of resistance to the diffusion of the cannabinoid
delta(9)-tetrahydrocannabinol (delta(9)-THC) in propyl-
ene glycol:water:ethanol (9:1:0.4).72 Our data are in
agreement with previous studies which demonstrated
that delta(8)-THC possess the same transdermal perme-
ability in human skin and guinea pig skin in vitro.73
Similarly, it has been shown that both WIN 55212-2
and CP55940 (synthetic cannabinoids) are very perme-
able through human skin in an in vitro system, in which
WIN55212-2 displays a more rapid transdermal diffu-
sion and higher deposition concentration in skin than
CP55940.74 The skin depot effect observed with
JWH015 in our studies could be reduced under in vivo
conditions due to the presence of the vasculature and
blood circulation, and/or by different solvents or vehi-
cles. However, our data indicate that keratinocytes and
fibroblasts would be exposed to the drug for relatively
long periods of time. This feature is clinically relevant
not only for the effects observed in our study but also for
the implications in terms of administration frequency
and patient compliance in clinical settings.
Conclusions
Selective CB2 receptor agonists have displayed promis-
ing results in animal pre-clinical models, however they
have yielded disappointing results in small clinical stu-
dies (capsaicin-induced pain model and tooth extraction
pain). A possible explanation for this lack of translata-
bility from the bench to the bedside is the differential
molecular or cellular functions or mechanisms between
rodents and humans. The use of human primary skin
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cells confers a high translational value to our studies, as
suggested in studies that have demonstrated that human
and rodent cells respond differently to stimuli and to
drugs (i.e. propentofylline, a glial modulator).18
Together, our data demonstrate that human keratino-
cytes and fibroblasts are ideal targets to cannabinoids
for the treatment of conditions with predominantly per-
ipheral inflammatory or injured tissue pathophysio-
logical mechanisms. Cannabinoid agonists seem to be
suitable to target skin cells due to their high lipophilic
nature. Direct actions on keratinocytes and fibroblasts
through CB1 and CB2 receptors will promote an anti-
inflammatory, yet pro-tissue repair phenotype. These
effects could also provide beneficial effects in conditions
accompanied by pain (burns, postoperative pain, arth-
ritis, war wounds, etc.). Our findings set the foundation
for testing this hypothesis using co-cultures with other
immune cells such as macrophages and in vivo models of
inflammation or tissue injury. This would set the foun-
dation for more informed clinical trials.
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